CorMedix (CRMD)
(Delayed Data from NSDQ)
$11.12 USD
-0.47 (-4.06%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $11.13 +0.01 (0.09%) 6:44 PM ET
1-Strong Buy of 5 1
C Value B Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRMD 11.12 -0.47(-4.06%)
Will CRMD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRMD
INCY Announces New Late-Stage Data on Skin Disease Drug
PBYI Surges 30% in 3 Months: How Should You Play the Stock?
CRMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
Other News for CRMD
Fell Below 50 Day Moving Average appears for CRMD after 8.38% move
Directional Movement Crossover Bearish appears for CRMD after 2.24% move
Cormedix’s Positive Outlook: Buy Rating Backed by Strong Sales Guidance and Strategic Initiatives
CRMD forms NR7 on September 12
NR7 appears for CRMD after 2.35% move